2003
Systematic review of NSAID-induced adverse reactions in patients with rheumatoid arthritis in Japan
Tomita T, Ochi T, Sugano K, Uemura S, Makuch R. Systematic review of NSAID-induced adverse reactions in patients with rheumatoid arthritis in Japan. Modern Rheumatology 2003, 13: 143-152. DOI: 10.1007/s10165-002-0214-5.Peer-Reviewed Original ResearchNonsteroidal antiinflammatory drugsProportion of patientsAdverse reactionsSystematic reviewGastrointestinal adverse reactionsRheumatoid arthritis patientsFixed-effects modelRA patientsArthritis patientsRheumatoid arthritisMost withdrawalsClinical trialsAntiinflammatory drugsPatientsTrialsDrugsRiskTotalEvent analysisArthritisReviewIncidenceProportionAdministrationEndpoint
2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint